Clinical studies could provide market moving news for Immuron in 2017

By Trevor Hoey. Published at Apr 7, 2017, in Biotech

Immuron Limited (ASX: IMC), a biopharmaceutical group focused on the treatment of gut mediated diseases has advised that the company’s IMM-124E Phase II clinical trial for the treatment of NASH (Non-Alcoholic Steatohepatitis) has successfully randomized its 134th subject, and that recruitment has now officially concluded.

By way of background, IMC is working towards the development and commercialisation of oral immunotherapeutics for the treatment of many gut mediated diseases. The company has a unique and safe technology platform that enables a shorter development therapeutic cycle.

IMC currently markets and sells Travelan® for the prevention of travellers’ diarrhea. However, the blue sky lies in its lead product candidate IMM-124E, which is in Phase 2 clinical trials for NASH and ASH. Management expects these products, together with the Company’s other pre-clinical immunotherapy pipeline products targeting immune-related diseases currently under development, will address a sizeable target market.

Share price experiences substantial rerating in March/April

While no doubt acknowledging the company’s achievements to date, investors appear to have an eye to the future as the company’s share price increased 50% between March and April. Having hit a high of 45 cents earlier this week, it has only retraced slightly, suggesting a significant degree of confidence in the company’s ability to deliver throughout 2017.

Of course it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

With regard to IMC’s IMM-124E phase II clinical trials for the treatment of NASH, the company had reached the recruitment goal of 120 randomized subjects earlier in the year. However, due to strong demand, the company allowed for subjects already in the screening process to complete screening and randomize into the study if eligible.

Commenting on what lies ahead for the remainder of the year, IMC’s Senior VP Head of Medical, Dr. Dan Peres commented, “The company is now scheduled for an interim analysis to be released towards the beginning of the third quarter of calendar year 2017, followed by topline results by the end of the year”.

Early feedback from global Principal Investigators (PIs) has been encouraging and IMC has already begun to establish a small working group to design the next phase of its clinical study.

Over the past 2 years, the company has made significant progress in strengthening the value of its NASH program, and expects to meet several other milestones by the end of 2017, some of which could significantly strengthen the company’s outlook.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.